Jazz Pharmaceuticals plc has filed a Marketing Authorization Application (MAA) to the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Vyxeos powder for concentrate for infusion to treat adults with high-risk acute myeloid leukemia (AML) defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).   The CHMP granted Vyxeos accelerated assessment, which is designed to reduce the review timeline for products of major inte...